Seoulin Bioscience Co.Ltd (038070) — Cash Flow-to-Debt Ratio
Seoulin Bioscience Co.Ltd (038070) has a Cash Flow-to-Debt Ratio of 0.02x as of December 2025, meaning its operating cash flow of ₩631.76 Million could theoretically repay 0% of its total liabilities (₩32.75 Billion) in one year. See Seoulin Bioscience Co.Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Seoulin Bioscience Co.Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Seoulin Bioscience Co.Ltd across 13 annual periods. Also explore Seoulin Bioscience Co.Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Seoulin Bioscience Co.Ltd (2013–2025)
Year-by-year debt coverage analysis for Seoulin Bioscience Co.Ltd. For market capitalisation and broader financial context, see Seoulin Bioscience Co.Ltd market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.15x | ₩4.76 Billion | ₩32.75 Billion | ▲ +155.6% |
| 2024 | -0.26x | ₩-4.61 Billion | ₩17.63 Billion | ▼ -972.3% |
| 2023 | 0.03x | ₩930.57 Million | ₩31.04 Billion | ▲ +135.2% |
| 2022 | -0.09x | ₩-4.36 Billion | ₩51.08 Billion | ▼ -159.0% |
| 2021 | 0.14x | ₩8.92 Billion | ₩61.71 Billion | ▼ -28.1% |
| 2020 | 0.20x | ₩3.68 Billion | ₩18.33 Billion | ▼ -42.3% |
| 2019 | 0.35x | ₩7.32 Billion | ₩21.00 Billion | ▲ +45.3% |
| 2018 | 0.24x | ₩4.17 Billion | ₩17.39 Billion | ▲ +260.4% |
| 2017 | 0.07x | ₩1.30 Billion | ₩19.54 Billion | ▼ -56.8% |
| 2016 | 0.15x | ₩2.76 Billion | ₩17.87 Billion | ▼ -22.1% |
| 2015 | 0.20x | ₩4.12 Billion | ₩20.80 Billion | ▲ +27.0% |
| 2014 | 0.16x | ₩2.74 Billion | ₩17.57 Billion | ▼ -40.6% |
| 2013 | 0.26x | ₩4.94 Billion | ₩18.82 Billion | — |